Zacks Investment Research disclosed Hologic, Inc. (NASDAQ:HOLX), hiking its price target to $43.00 earlier today
- Updated: September 28, 2016
Yesterday Hologic, Inc. (NASDAQ:HOLX) traded -0.12% lower at $38.76. The company’s 50-day moving average is $38.34 and its 200-day moving average is $35.98. The last closing price is up 7.61% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 879,210 shares of the stock were exchanged, down from an average trading volume of 2,348,140
Reporting a potential upside of 0.11%, Zacks Investment Research raised the target price of Hologic, Inc. (NASDAQ:HOLX) to $43.00
Previously on 9/23/2016, Barclays reported on Hologic, Inc. (NASDAQ:HOLX) raised the target price from $42.00 to $44.00. At the time, this indicated a possible upside of 0.13%.
See Chart Below
Hologic, Inc. has a 52 week low of $31.84 and a 52 week high of $41.66 with a P/E ratio of 42.69 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its target price, a total of 16 brokers have issued a report on the stock. The consensus target price is $42.25 with 8 brokers rating the stock a strong buy, 5 brokers rating the stock a buy, 8 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About Hologic, Inc. (NASDAQ:HOLX)
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays. Its Breast Health products include a portfolio of breast imaging and related products and accessories, including digital mammography systems, computer-aided detection for mammography and minimally invasive breast biopsy devices, breast biopsy site markers and breast biopsy guidance systems. Its GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. Its Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.